1 / 11

Safety and Efficacy of Advanced Surface Ablation for Extreme Myopia, Hyperopia, and Astigmatism

Safety and Efficacy of Advanced Surface Ablation for Extreme Myopia, Hyperopia, and Astigmatism . Sze H. Wong, BS Lynnette P. Williams, MD Emil W. Chynn, MD. The authors have no financial interest in the subject matter of this poster.

gittel
Download Presentation

Safety and Efficacy of Advanced Surface Ablation for Extreme Myopia, Hyperopia, and Astigmatism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Safety and Efficacy of Advanced Surface Ablation for Extreme Myopia, Hyperopia, and Astigmatism Sze H. Wong, BS Lynnette P. Williams, MD Emil W. Chynn, MD The authors have no financial interest in the subject matter of this poster. LASEK or Epi-LASIK to treat extreme refractive errors is not FDA-approved.

  2. PURPOSE To determine whether extreme prescriptions may be safely and effectively treated with advanced surface ablation techniques

  3. METHOD • Retrospective review of eyes that underwent LASEK or Epi-LASEK with a VISX S4IR excimer laser. Eyes that had monovision were excluded • Adjunctive treatment to prevent scarring: • Mitomycin C (MMC) 0.01% intraoperatively • Oral steroids: 1-3 wks postop • Topical steroids: 2-6 mo postop • Vitamin C: 2-6 mo postop • UV protection: 3-12 mo postop

  4. Study Population: Characteristics

  5. RESULTS:Uncorrected Visual Acuity(UCVA) (20/2000) error bar = standard deviation (20/200) (20/20)

  6. Gain in VA at 3 months Postop UCVA vs. Preop Best Ccorrected Visual Acuity (BCVA) 100 % of eyes had postop UCVA > preop UCVA

  7. Postop UCVA vs. Preop BCVA error bar = standard deviation (0.99 line VA) (0.37 line VA) (0 line VA)

  8. Postop UCVA vs. Preop BCVA (%)

  9. Eyes With Postop UCVA < Preop BCVA

  10. Complications • 11/153 (7 %) of eyes had postop haze (tr to 2+) • 3/153 (2%) of eyes lost ≥ 1 line of BCVA due to postop haze • 1/153 (0.7%) of eyes lost ≥ 2 lines of BCVA due to postop haze

  11. CONCLUSION • Extreme prescriptions may be safely and effectively treated with advanced surface ablation, combined with adjunctive treatments to prevent scarring • 72% eyes: 3-mo. postop UCVA ≥ preop BCVA • Further studies are needed to determine whether extremely hyperopic eyes are more likely to lose BCVA and how to avoid this loss

More Related